MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer

Cancer Biology and Therapy

Volumn 7, Issue 8, 2008, Pages 1288-1296

  Rokhlin, Oskar W ^a   Scheinker, Vladimir S ^b   Taghiyev, Agshin F ^a   Bumcrot, David ^c   Glover, Rebecca A ^a   Cohen, Michael B ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Xenomics Inc   (United States)

^c ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

Androgen; Androgen receptor; Apoptosis; Kinases; MicroRNA 34

Indexed keywords

ANDROGEN RECEPTOR; CAMPTOTHECIN; CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; MICRORNA; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; PACLITAXEL; PROTEIN P53; SMALL INTERFERING RNA; TRICHOSTATIN A; TUMOR NECROSIS FACTOR; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CONTROLLED STUDY; DNA STRAND BREAKAGE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 49749151009     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.8.6284     Document Type: Article

References (35)

1. Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death and Differentiation 2007; 14:3-9.
2. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nature Rev 2004; 4:793-805.
3. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathway in LNCaP. Oncogene 2005; 24:6773-84.
4. He L, He X, Lowe SW, Hannon GJ. MicroRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nature Rev Cancer 2007; 7:819-22.
5. He X, He L, Hannon GJ. The Guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67:11099-101.
6. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. Nature 2007; 447:1130-4.
7. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67:8433-8.
8. 1-arrest. Cell Cycle 2007; 6:1586-93.
9. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007; 26:731-43.
10. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26:745-52.
11. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Rev Genetics 2008; 9:102-14.
12. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can upregulate translation. Science 2007; 318:1931-34.
13. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 2004; 10:33-9.
14. Liao X, Tang S, Thrasher JB, Griebling T, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005; 4:505-15.
15. Yang Q, Fung KM, Day WV, Kropp BP, Lin HK. Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Intern 2005; 5:1-10.
16. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 2006; 66:10613-20.
17. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansky VE, Glover RA, Cohen MB. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Therapy 2007; 6:732-42.
18. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997; 57:1758-68.
19. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Syrbu SI, Cohen MB. TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 2002; 1:631-7.
20. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, Bacallado SA, Nguyen DN, Fuller J, Alvarez R, Borodovsky A, Borland T, Constien R, de Fougerolles A, Dorkin JR, Narayanannair Jayaprakash K, Jayaraman M, John M, Koteliansky V, Manoharan M, Nechev L, Qin J, Racie T, Raitcheva D, Rajeev KG, Sah DW, Soutschek J, Toudjarska I, Vornlocher HP, Zimmermann TS, Langer R, Anderson DG. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 5:561-9.
21. Li Y, Hu J, Vita R, Sun B, Tabata H, Altman A. SPAK kinase is a substrate and target of PKCØ in T-cell receptor-induced AP-1 activation pathway. EMBO J 2004; 23:1112-22.
22. Sedarous M, Keramaris E, O'Hare M, Melloni E, Slack RS, Elce JS, Greer PA, Park DS. Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 2003; 278:26031-38.
23. Johnston AM, Naselli G, Gonez LJ, Martin RM, Harrison LC, DeAizpurua HJ. SPAK, a STE20/SPS1-related kinase that activates the p38 pathway. Oncogene 2000; 19:4290-97.
24. Qi H, Labrie Y, Grenier J, Fournier A, Fillion C, Labrie C. Androgens induce expression of SPAK, a STE20/SPS1-related kinase, in LNCaP human prostate cancer cells. Mol Cell Endocrinology 2001; 182:181-92.
25. Stucki M, Jackson SP. MDC1/NFBD1: a key regulator of the DNA damage response in higher eukaryotes. DNA Repair 2004; 3:953-7.
26. Nakanishi M, Ozaki T, Yamamoto T, Kikuchi H, Furuya K, Asaka M, Delia D, Nakagawara A. NFBD1/MDC1 associates with p53 and regulates its function at the crossroat between cell survival and death in response to DNA damage. J Biol Chem 2005; 282:22993-3004.
27. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts, Skakkebaek NE, Stucki M, Jackson S, Lukase J, Bartek J. DNA damage response mediators MDC1 and 53BP1 constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ tumours. Oncogene 2005; 26:7414-22.
28. Schmitt JM, Guire ES, Saneyoshi T, Sodering TR. Calmodulin-dependent kinase kinase/calmodulin kinase I activity gates extracellular-regulated kinase-dependent long-term potentiation. J Neuroscience 2005; 25:1281-90.
29. Wang Q, Li W, Liu S, Caroll JS, Janne OA, Keeton EK, Chinnaiyan AM, Pienta KJ, Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27:380-92.
30. Jasavala R, Martinez H, Thumar J, Andaya A, Gingras AC, Eng JK, Aebersold R, Han DK, Wright ME. Identification of putative androgen receptor interaction protein modules. Mol Cell Proteomics 2007; 6:252-71.
31. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99:333-44.
32. Goldberg M, Stucki M, Falck J, D'Amours D, Rahman D, Pappin D, Jiri B, Jackson SP. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature 2003; 421:952-56.
33. Lou Z, Minter-Dykhouse K, Wu X, Chen J. MDC1 is coupled to activated CHK2 in mammalian DNA damage response pathways. Nature 2003; 421:957-61.
34. Stewart GS, Wamg B, Bignell CR, Taylor AMR, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint.Nature 2003; 421:961-66.
35. Gurova KV, Rokhlin OW, Budanov AV, Burdelya LG, Chumakov PM, Cohen MB, Gudkov AV. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer res 2003; 63:2905-12.